Anti-inflammation and anti-cancer effects of Naringenin combination with Artemisinins in human lung cancer cells

Background: Naringenin is a well-known flavonoid agent with a significant anti-microbial and anti-cancer effect to induce apoptosis and suppress tumor growth in different malignancies such as lung cancer. Artemisinins, a family of sesquiterpene trioxane is known to have powerful therapeutic functions including anticancer and anti-inflammatory effects. Therefore, in the present study, we aimed to assess anti-cancer and anti-inflammation effect of Naringenin in combination with Artemisinin to develop an effective therapeutic target for lung Cancer. Method: Cells were treated with Naringenin (50 mu g/ml) in combination with various concentrations of Artemisinins (10-50 mu g/ml). Cell viability, PKA activity, cAMP concentration and pro-inflammatory cytokines levels were determined by using MTT assay, colorimetric measurement and Enzyme-linked immunosorbent assay respectively. Result: Our results confirmed that Naringenin (50 mu g/ml) combination with increasing dosage of Artemisinins could significantly inhibit cell growth, and the pro-inflammatory cytokines via increasing the PKA and cAMP levels in human A549 lung cancer cell line. Conclusion: Our results indicate that Artemisinins and Naringenin combination could become an effective therapeutic agent via inhibiting the cell viability, and inflammatory cytokines in human lung cancer.